Symposium on preclinical research and application of innovative drugs

Activity theme: preclinical research and application of innovative drugs held on January 10, 2019 (Thursday) conference hosted by Shanghai medixi biomedical Co., Ltd conference location: Chengdu (send specific address after successful application) conference introduction Medeci will launch a series of tour activities for the 15th anniversary of "work together with you to help new drugs" We invite you to witness our service ability and all efforts in the development process of preclinical research of new drugs, and share and discuss the details of new drug research and development On January 10, we will take Chengdu as the third stop of the tour seminar, with the theme of "preclinical research and application of innovative drugs", and comprehensively discuss with you how to carry out preclinical research and registration application strategically in new drug research and development? How to effectively reduce the risk of new drug development? Help you to quickly promote drug research and development to the clinical stage! Introduction (in order of speech) Dr Chen Chunlin, chief executive officer, graduated from China Pharmaceutical University in 1986 with a master's degree in pharmacy and from Oklahoma State University in 1994 with a doctor's degree in pharmacology and toxicology, EMBA of China Europe Business School After graduation, he has been engaged in many years of pharmaceutical pharmacology, toxicology and biochemistry research, and has profound knowledge in the design of cardiovascular drugs, pharmacokinetics and metabolism of new anti AIDS and anti-cancer drugs At the beginning of 2004, he returned to China to establish Shanghai meidixi biomedical Co., Ltd At present, he is the vice chairman of the pharmacokinetic Committee of Shanghai Pharmacology Society and vice chairman of Shanghai Pudong biomedical Association At the same time, he is also employed as a visiting professor of the school of life sciences of China Pharmaceutical University Dr Peng Shuangqing, vice president of preclinical research department and head of institution, researcher and doctoral supervisor of Academy of Military Medical Sciences He served as the vice president of China Society of toxicology, executive director of China Society of environmental mutagens and other academic positions He has been engaged in the safety evaluation and GLP management of innovative drugs for a long time, undertaken the construction of national GLP technology platform supported by the Ministry of science and technology of the people's Republic of China, presided over and undertaken more than 40 national scientific research projects, including 973 projects, 863 Program projects and national "major new drug creation" science and technology projects He has published more than 280 scientific research papers, including more than 100 SCI academic papers and 12 monographs edited (participated in) 12 scientific and technological achievements have won national, provincial and ministerial achievement awards He has won the government special allowance of the State Council, the post allowance for outstanding military talents, the honorary title of "excellent scientific and technological worker" of China Association for science and technology, and the outstanding contribution award of China Society of toxicology To guide and train more than 90 master's and postdoctoral students He is a new drug review expert of the State Food and drug administration, a medical device review expert, a new chemical review expert of the Ministry of environmental protection and a vice editor in chief of environmental toxicology and pharmacology Dr Xin Baomin, vice president of biological analysis department, Ph.D in chemistry, Brigham Young University, USA, has 17 years of experience in new drug research and development in foreign pharmaceutical enterprises He was the chief scientist of BMS and researcher of DuPont pharmaceutical company Led the team to participate in the research and development of new drugs and achieved the listing of several new drugs, among which the annual sales volume of eliquis, a new drug targeting FXa clotting factor, has exceeded 3 billion US dollars During his doctoral study, he designed a new type of time-of-flight mass spectrometer, which was adopted by sensor company and developed into a product (Jaguar) for sale He once served as the executive director of the biological analysis department of Wuxi Pharmaceutical Co., Ltd., providing GLP biological analysis services for domestic and foreign pharmaceutical enterprises, passed CFDA inspection for more than 20 times, and passed FDA inspection with zero defects A 4-and-a-half-day cfdai training course on standardization of biological sample analysis in clinical experiments was held for CFDA high Research Institute of State Food and drug administration The course included lectures, laboratories and advanced biological analysis talents with international GLP level Now he is executive member of North American CACA society Dr Ma Fei, executive director of the early pharmacokinetic office, master's degree, China Pharmaceutical University, and doctor of pharmacokinetic, University of Tennessee, USA He used to be a drug metabolism researcher of GTX company, senior scientist of drug metabolism of seventh wave laboratories company, assistant director and deputy director of pharmacokinetic Department of Shanghai smart chemical In 2016, he joined medecipua, served as senior director of biological analysis room, and now is executive director of early pharmacokinetics room Dr Zhang Xiaodong, vice president of preclinical toxicology, Secretary of the Department of Tropical Medicine and public health of the Second Military Medical University, branch secretary, deputy director, associate professor and master tutor of the drug safety evaluation center of the Second Military Medical University Person in charge of general toxicology department and clinical laboratory Expert of new drug evaluation of State Food and drug administration, member of drug toxicology Committee of Chinese Pharmacology Society, member of drug toxicology and safety evaluation committee of Chinese Toxicology Society Dr Hu Zheyi, director of pharmacology department, master and doctor of pharmacology, China Pharmaceutical University In 2006, he joined Medici and engaged in the research and development of anti-tumor drugs for a long time During his work in medeci, he led the research team to establish and evaluate a large number of different types of tumor animal models, and participated in more than ten anti-tumor drug research and new drug application work of domestic and foreign pharmaceutical companies Dr Gu xingchu, vice president of preclinical research department, served as director of Toxicology Research Office of Shanghai Pharmaceutical Industry Research Institute and executive vice director of Shanghai new drug safety evaluation research center The major fields are drug safety evaluation research and GLP management As a visiting scholar, he studied preclinical drug research for two years in Hearst pharmaceutical company, Germany, and visited GLP laboratories in the United States, Canada and Australia He has been responsible for and completed one 973 sub project of the Ministry of science and technology, two projects of the national youth new drug fund and ten projects of the Shanghai Science Fund As the main researcher, he participated in three national key projects Won the second prize of Shanghai Science and technology progress in 2001 He is a member of Chinese society of toxicology and other professional societies Member of the expert database of new drug review and GLP audit of the State Food Administration Dr Zeng Xiancheng, director of toxicology research department, has 8 years of experience in preclinical drug generation and safety assessment research, has received 8 months of theoretical and technical training in drug application and evaluation in CDE, and has accumulated rich experience in preclinical drug generation and safety assessment design, implementation, data comprehensive analysis and evaluation of different types of new drugs As the project leader, 13 preclinical drug generation and safety assessment studies of class 1 chemicals have been completed, 10 of which have passed the CFDA or FDA review at one time, and the other 3 are waiting for declaration; 3 preclinical drug generation and safety assessment studies of ADC drugs, 2 of which have passed the CFDA or FDA review, and the other one is being reviewed by CFDA; 2 preclinical drug generation and safety assessment studies of compound chemicals have been completed Dr Dong Wenxin, senior director of the pharmacodynamic department, went to the six medical schools in Paris and the National Academy of Medical Sciences of France to study from 1991 to 1997 He obtained a master's degree and a doctor's degree in pharmacology He was once a researcher and doctoral supervisor of Shanghai Pharmaceutical Industry Research Institute, a director of Shanghai Pharmaceutical Association, a vice chairman of Shanghai Pharmaceutical Professional Committee, and a special allowance winner of the State Council He has been engaged in pharmacological research and new drug development for a long time, mainly involving the research fields of cardiovascular and cerebrovascular system and neuropsychopharmacology He has undertaken a number of national and municipal major new drug innovation projects The technical platform for the research and development of antidepressant and anti Alzheimer's new drugs and pharmacology and pharmacology has been established in China, and has built a new platform for pharmacology and pharmacology research and development of new analgesic drugs, anti anxiety drugs and anti Parkinson's new drugs Responsible for completing dozens of preclinical research tasks of new drugs Dr Ma Jianguo, vice president of chemistry department, doctor of organic synthesis, University of Montreal, and postdoctoral, Department of chemistry, Harvard University He was a senior technical R & D personnel of American pharmaceutical companies AstraZeneca and sepracor / sunovicon After returning to China in 2012, he served as the R & D vice president of the listed company asymchem and the CTO of Chongqing boten Pharmaceutical Technology Co., Ltd He has many years of experience in research and development of first-class new drugs, and has led and participated in a number of major innovative drug and generic drug research projects It also has rich experience in R & D of API and intermediates production process, and has developed more than 20 kinds of API and many pharmaceutical intermediates commercial production processes with cost advantages and intellectual property rights Zhou Xiaotang, director of CMC, graduated from Shenyang Pharmaceutical University with a master's degree in pharmaceutics, International Pharmaceutical Engineering Management (IPEM) of Peking University, and mini MBA of China Europe Business School With more than ten years of working experience in pharmaceutical research and development, focusing on high-end pharmaceutical research and development, with rich experience in solid sustained and controlled release, compound preparation, inhalation preparation, suspension and sterile preparation, etc., he has been engaged in the research of new drugs, generic drugs and new dosage forms in Hengrui pharmaceutical Experience in R & D and application of multiple innovative drugs I / II preclinical, first generic, consistency evaluation varieties, complex preparations and international projects, as well as rich experience in preparation pilot scale-up, workshop construction and GMP Ren Feng, vice president of chemistry and biology, graduated from the Department of chemistry, Harvard University in 2007 He has 11 years of experience in R & D of small molecule innovative drugs in multinational pharmaceutical companies (GlaxoSmithKline) He has successively served as the chief researcher, deputy director, director and head of Chemical Department of GlaxoSmithKline R & D department We have successfully developed several clinical candidate compounds / clinical phase I compounds for the treatment of Parkinson's disease, multiple sclerosis, ankylosing spondylitis, and pain In 2018, he joined Medici as vice president and was fully responsible for the R & D service business of the chemistry department and the biology department Conference registration 1 This forum aims to build a communication platform for the industry, which is open to the participants free of charge Registration deadline: January 8 2 The real name system shall prevail Please click "read the original" at the end of the article to register 3 We will send the registration receipt information (including the meeting address) before January 9, and the receipt will be regarded as the successful registration For more details of the meeting, please scan the QR code or log in to www.medicilon.com.cn contact person: Ge Yuping contact number: 021-58591500-8951 13524599056 email: ypge@medicilon.com.cn No.585 Chuanda Road, Pudong New Area, Shanghai